Cellectis, Pfizer to develop CART therapies for cancer
Pfizer Inc. and oncology firm Cellectis SA teamed up to develop chimeric antigen receptor T-cell (CART) cancer immunotherapies aimed at 15 targets selected by the Big Pharma and 12 targets chosen by Cellectis.
- Gene Therapy, Cell Therapy
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com